BACK TO CONTENTS   |    PDF   |   

Title

Molecular docking analysis of Cianidanol from Ginkgo biloba with HER2+ breast cancer target

 

Authors

Abiodun Julius Arannilewa1,2, Oluwaseun Suleiman Alakanse1, Adesola Oluwaseun Adeleye3,
Oluwaseyi Israel Malachi5, Ifedayo Michael Obaidu2,6, Oluwafemi Emmanuel Ekun4, Emmanuel
Damilola Afolayan1, Patricia Folakemi Afere1,3, Kayode Abdullateef Ayuba1, Tolulope Oluwafemi
Bolarinwa3, George Oche Ambrose1

 

Affiliation

1Department of Biochemistry, University of Ilorin, Ilorin, Nigeria; 2Department of Biochemistry, Ekiti State University, Ado Ekiti, Nigeria; 3Department of Biochemistry, Federal University of Technology, Akure, Nigeria; 4Department of Biochemistry, Adekunle Ajasin University, Akungba Akoko, Nigeria; 5Food Production Department, Goodfoods Inc., Montreal, QC, Canada; 6Department of Biochemistry, University of Ibadan, Ibadan, Nigeria

 

Email

Abiodun Julius Arannilewa - E-mail: arannilewajuliusabiodun@yahoo.com

 

Article Type

Hypothesis

 

Date

Received October 2, 2018; Revised October 8, 2018; Accepted October 9, 2018; Published November 21, 2018

 

Abstract

HER2 is a known therapeutic target for about 30% of breast cancer patients where HER2 is over expressed and this is referred to as HER2 positive breast cancer. This subtype is characterized by a clinical behavior know to be especially aggressive. Improved HER2 targeting agents such as trastuzumab, pertuzumb, lapatinib and ado-trastuzumab emtansine are available. Some patients have shown no response to treatment while others show progress to these agents. Therefore, it is of interest to screen HER2+ with phyto-chemical lead compound from Ginkgo biloba using molecular docking techniques. We screened 25 phyto-chemicals from literature with HER2+. Results show that cianidanol have an acceptable binding energy of (-8.2kcal/mol). Thus, we report the binding properties of cianidanol with HER2+.

 

Keywords

Cianidanol, Ginkgo biloba, HER2.

 

Citation

Arannilewa et al. Bioinformation 14(9) 482-487 (2018)

 

Edited by

P Kangueane

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.